Denali Therapeutics Inc. — FY2022 Form 10-K
Reporting period: Fiscal year ended December 31, 2022. Denali is a clinical-stage biotechnology company developing medicines for neurodegenerative and lysosomal storage diseases, including therapies engineered to cross the blood-brain barrier. It had no approved products and generated no product-sales revenue; reported revenue came from collaborations and licenses.
Financial performance and position
| Metric | FY2022 | FY2021 | Change / context |
|---|---|---|---|
| Collaboration revenue | $108.5 million | $48.7 million | Up $59.8 million, primarily from Takeda and Sanofi milestones and recognition of remaining ATV:Tau program revenue |
| Research and development expense | $358.7 million | $265.4 million | Up 35%, reflecting increased clinical and platform investment |
| General and administrative expense | $90.5 million | $79.1 million | Up 14% |
| Operating loss | $340.7 million | $295.8 million | Loss widened |
| Net loss | $326.0 million; $2.60 per share | $290.6 million; $2.39 per share | Loss widened 12%; 2020 had net income of $71.1 million, largely reflecting Biogen collaboration revenue |
| Operating cash flow | $(244.7) million | $(211.4) million | Higher cash use |
| Cash, cash equivalents and marketable securities | $1.336 billion | $1.291 billion | Includes $1.118 billion of short-term marketable securities at year-end 2022 |
Liquidity and balance sheet: Current assets were $1.372 billion and current liabilities were $363.9 million, implying working capital of about $1.008 billion. Total liabilities were $417.8 million, including $60.4 million of operating lease liabilities and collaboration contract liabilities. The filing reports no borrowings in the presented balance sheet. Stockholders’ equity was $1.042 billion and accumulated deficit was $971.0 million. The company raised approximately $296.2 million net from its October 2022 common-stock offering.
Margins: Conventional product gross margins are not meaningful because Denali had no product sales. Operating expenses substantially exceeded collaboration revenue. Interest and other income was $14.8 million, up from $4.6 million, primarily reflecting its larger investment portfolio and interest-rate environment.
Material changes and business developments
- Collaboration revenue more than doubled, while operating expenses rose 30% and net loss increased by $35.4 million. Revenue is milestone- and collaboration-dependent and may vary substantially between periods.
- R&D spending increased mainly for DNL310’s Phase 1/2 and Phase 2/3 studies, the broader Transport Vehicle platform, PTV:PGRN, and LRRK2 development. Personnel-related R&D expense also rose.
- FY2022 operating cash use was partly offset by $310.7 million in financing cash flow, primarily the October offering. Investing cash use was $141.4 million, including purchases and maturities of marketable securities and $17.8 million of capital expenditures.
- Denali reported seven clinical-stage candidates across eight indications. Major partnered programs include Biogen’s LRRK2 inhibitor BIIB122/DNL151, Sanofi’s RIPK1 inhibitors, and Takeda’s PTV:PGRN and ATV:TREM2 programs.
- Takeda and Denali ended activity on ATV:Tau in 2022; Denali recognized $27.9 million of previously deferred revenue related to the termination. Takeda CTA approvals generated $24.0 million of milestones, and Sanofi milestones included $40.0 million for ALS and $10.0 million for ulcerative colitis.
Outlook, commentary and key risks
- Management said year-end cash, cash equivalents and marketable securities should fund projected operations through at least 12 months after the February 27, 2023 filing date. This estimate depends on assumptions; the company expects substantial additional funding will be needed longer term.
- Planned 2023 activities included continued enrollment in DNL310’s global Phase 2/3 COMPASS trial; DNL126 (ETV:SGSH) IND submission in the first half of 2023; anticipated initiation of DNL343’s Phase 2/3 HEALEY ALS Platform Trial around mid-2023; and continued enrollment in partnered Parkinson’s, ALS and MS studies. These are plans, not guaranteed outcomes.
- DNL310 interim Phase 1/2 results reported in February 2023 showed sustained CSF heparan-sulfate reductions and exploratory clinical measures of improvement or stabilization; safety was described as consistent with standard-of-care enzyme replacement therapy through up to two years. Results remain interim, and the Phase 2/3 study is ongoing.
- The FDA placed the TAK-920/DNL919 (ATV:TREM2) IND on clinical hold in January 2022 over preclinical toxicology and requested information. A Phase 1 study was underway in the Netherlands; the regulatory path forward remained under discussion.
- Principal risks include clinical or regulatory failure, trial delays and enrollment challenges, uncertainty around whether BBB delivery translates into clinical benefit, manufacturing and supply constraints, dependence on collaborators, competition, intellectual-property exposure, and potential need for further capital. Denali relies on third-party manufacturers and reported delays in its Utah clinical-manufacturing-site build-out.
- The company had no material litigation identified by management. Ernst & Young issued unqualified opinions on the financial statements and internal control over financial reporting; the audit highlighted estimation of accrued R&D costs as a critical audit matter.
Important facts for investors to verify
- Latest DNL310 Phase 2/3 enrollment, safety, and clinical-outcome results, and whether interim biomarker changes predict meaningful patient benefit.
- Regulatory resolution and further clinical progress for TAK-920/DNL919 following the FDA hold.
- Whether DNL343’s planned Phase 2/3 entry and DNL126’s planned IND submission occurred on schedule, and subsequent data.
- Quarterly cash use, collaboration milestone timing, and whether the stated cash runway remains valid as development spending grows.
- Utah facility completion and manufacturing readiness, along with any resulting changes to capital needs or clinical supply.
- Potential dilution and share-count effects from future financing; 135.97 million shares were outstanding at December 31, 2022, and 136.68 million at February 21, 2023.